These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19916996)

  • 1. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
    He X; Hesse LM; Hazarika S; Masse G; Harmatz JS; Greenblatt DJ; Court MH
    Br J Clin Pharmacol; 2009 Nov; 68(5):721-30. PubMed ID: 19916996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
    Court MH; Hao Q; Krishnaswamy S; Bekaii-Saab T; Al-Rohaimi A; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2004 Aug; 310(2):656-65. PubMed ID: 15044558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
    Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
    Court MH; Duan SX; Guillemette C; Journault K; Krishnaswamy S; Von Moltke LL; Greenblatt DJ
    Drug Metab Dispos; 2002 Nov; 30(11):1257-65. PubMed ID: 12386133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation.
    Hanioka N; Oka H; Nagaoka K; Ikushiro S; Narimatsu S
    Arch Toxicol; 2011 Nov; 85(11):1373-81. PubMed ID: 21404072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
    Nishihara M; Hiura Y; Kawaguchi N; Takahashi J; Asahi S
    Drug Metab Pharmacokinet; 2013; 28(6):475-84. PubMed ID: 23648677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
    Stringer F; Scott G; Valbuena M; Kinley J; Nishihara M; Urquhart R
    Eur J Clin Pharmacol; 2013 Mar; 69(3):423-30. PubMed ID: 22960998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y).
    Lampe JW; Bigler J; Bush AC; Potter JD
    Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):329-33. PubMed ID: 10750673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.
    Ménard V; Eap O; Harvey M; Guillemette C; Lévesque E
    Hum Mutat; 2009 Sep; 30(9):1310-9. PubMed ID: 19572376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of UDP-glucuronosyltransferase (UGT2B15) and glucuronidation of paracetamol in healthy population.
    Mehboob H; Iqbal T; Jamil A; Khaliq T
    Pak J Pharm Sci; 2016 May; 29(3 Suppl):1037-41. PubMed ID: 27383482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of the microRNA response elements in the 3'-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach.
    Papageorgiou I; Court MH
    Biochem Pharmacol; 2017 Dec; 146():199-213. PubMed ID: 28962835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
    Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
    Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.
    Park J; Chen L; Shade K; Lazarus P; Seigne J; Patterson S; Helal M; Pow-Sang J
    J Urol; 2004 Jun; 171(6 Pt 1):2484-8. PubMed ID: 15126881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uridine diphosphate-glucuronosyltransferase 2B15 D85Y gene polymorphism is associated with lower prostate cancer risk: a systematic review and meta-analysis.
    Zhong X; Feng J; Xiao Y; Wang P; Fan Q; Wu R; Hu W; Huang C
    Oncotarget; 2017 Aug; 8(32):52837-52845. PubMed ID: 28881775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of human UDP-glucuronosyltransferase UGT2B17 regio-specificity by a single amino acid substitution.
    Dubois SG; Beaulieu M; Lévesque E; Hum DW; Bélanger A
    J Mol Biol; 1999 May; 289(1):29-39. PubMed ID: 10339403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer.
    MacLeod SL; Nowell S; Plaxco J; Lang NP
    Ann Surg Oncol; 2000 Dec; 7(10):777-82. PubMed ID: 11129427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15.
    Wilson W; Pardo-Manuel de Villena F; Lyn-Cook BD; Chatterjee PK; Bell TA; Detwiler DA; Gilmore RC; Valladeras IC; Wright CC; Threadgill DW; Grant DJ
    Genomics; 2004 Oct; 84(4):707-14. PubMed ID: 15475248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism.
    Strahm E; Sjöberg U; Garle M; Rane A; Ekström L
    Front Endocrinol (Lausanne); 2013; 4():75. PubMed ID: 23805127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers.
    Chung JY; Cho JY; Yu KS; Kim JR; Jung HR; Lim KS; Jang IJ; Shin SG
    Clin Pharmacol Ther; 2005 Jun; 77(6):486-94. PubMed ID: 15961980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
    Stringer F; Ploeger BA; DeJongh J; Scott G; Urquhart R; Karim A; Danhof M
    J Clin Pharmacol; 2013 Mar; 53(3):256-63. PubMed ID: 23444281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.